18:57 , Jan 17, 2019 |  BC Week In Review  |  Company News

Sanofi expands multitargeting toolbox with Biomunex deal

Sanofi (Euronext:SAN; NASDAQ:SNY) has expanded its toolbox for developing multispecific modalities through a licensing deal with Biomunex Pharmaceuticals (Paris, France). The deal gives Sanofi access to Biomunex's Plug-and-Play BiXAb platform, which generates bi-specific and multispecific...
23:26 , Jan 15, 2019 |  BC Extra  |  Company News

Sanofi expands multitargeting toolbox with Biomunex deal

Sanofi (Euronext:SAN; NASDAQ:SNY) has expanded its toolbox for developing multispecific modalities through a licensing deal with Biomunex Pharmaceuticals (Paris, France). The deal gives Sanofi access to Biomunex's Plug-and-Play BiXAb platform, which generates bi-specific and multispecific...
22:48 , Dec 20, 2018 |  BC Extra  |  Company News

Management tracks: Evox names Moses chairman; Kapeller joins GV

Exosome therapy company Evox Therapeutics Ltd. (Oxford, U.K.) appointed Edwin Moses as chairman. This month, the former Ablynx N.V. CEO was also appointed chairman of Virion Biotherapeutics Ltd. (London, U.K.) and Achilles Therapeutics Ltd. (Stevenage,...
22:09 , Dec 17, 2018 |  BC Extra  |  Company News

Management tracks: Vertex’s Graney joins Generation Bio

Tom Graney has left Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) as CFO to take on the same role at non-viral gene therapy company Generation Bio Co. (Cambridge, Mass.). Ian Smith, Vertex EVP and COO and former CFO,...
00:39 , Dec 11, 2018 |  BC Extra  |  Company News

Management tracks: Grail, EUSA

Cancer detection company Grail Inc. (Menlo Park, Calif.) appointed Catherine Friedman chairman. She succeeds Bill Rastetter, who will continue as a director. Friedman joined Grail's board last year and also serves on the board of...
18:30 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

Sanofi's Cablivi gains EU approval, Priority Review in U.S.

Sanofi (Euronext:SAN; NYSE:SNY) said the European Commission approved Cablivi caplacizumab to treat rare blood clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP). The company also revealed Sept. 3 that FDA accepted and granted Priority Review to...
18:18 , Sep 3, 2018 |  BC Extra  |  Company News

Sanofi's Cablivi gains EU approval, Priority Review in U.S.

Sanofi (Euronext:SAN; NYSE:SNY) said the European Commission approved Cablivi caplacizumab to treat rare blood clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP). The company also revealed Monday that FDA accepted and granted Priority Review to its...
19:29 , Aug 1, 2018 |  BC Innovations  |  Emerging Company Profile

Connecting the DotBodies

Cancer play DotBio Pte. Ltd. launched this week with a screening platform to discover and develop products based on humanized domain antibodies that could be more stable and easier to manufacture than other domain antibodies....
23:21 , Jul 13, 2018 |  BioCentury  |  Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
20:07 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

EMA's CHMP recommends CAR Ts, rare disease therapies

EMA's CHMP recommended for approval Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel, the first two CAR T therapies backed by the committee. CHMP also recommended a handful of other Orphan drug candidates, including Cablivi caplicizumab, a...